In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2

SARS-CoV-2 is the etiological agent of COVID-19, which represents a global health emergency that was rapidly declared a pandemic by the World Health Organization. Currently, there is a dearth of effective targeted therapies against viruses. Natural products isolated from traditional herbal plants ha...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biomolecular structure & dynamics 2022-07, Vol.40 (13), p.5917-5931
Main Authors: Junior, Nilson Nicolau, Santos, Igor Andrade, Meireles, Bruno Amaral, Nicolau, Mariana Sant'Anna Pereira, Lapa, Igor Rodrigues, Aguiar, Renato Santana, Jardim, Ana Carolina Gomes, José, Diego Pandeló
Format: Article
Language:English
Subjects:
COVID-19
lapachol derivatives
Nsp9
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c468t-cbca66cf287e0a83bf647d9fe085db8f85375a1d0a85bfa9d1390823f669d93a3
cites cdi_FETCH-LOGICAL-c468t-cbca66cf287e0a83bf647d9fe085db8f85375a1d0a85bfa9d1390823f669d93a3
container_end_page 5931
container_issue 13
container_start_page 5917
container_title Journal of biomolecular structure & dynamics
container_volume 40
creator Junior, Nilson Nicolau
Santos, Igor Andrade
Meireles, Bruno Amaral
Nicolau, Mariana Sant'Anna Pereira
Lapa, Igor Rodrigues
Aguiar, Renato Santana
Jardim, Ana Carolina Gomes
José, Diego Pandeló
description SARS-CoV-2 is the etiological agent of COVID-19, which represents a global health emergency that was rapidly declared a pandemic by the World Health Organization. Currently, there is a dearth of effective targeted therapies against viruses. Natural products isolated from traditional herbal plants have had a huge impact on drug development aimed at various diseases. Lapachol is a 1,4- naphthoquinone compound that has been demonstrated to have therapeutic effects against several diseases. SARS-CoV-2 non-structural proteins (nsps) play an important role in the viral replication cycle. Nsp9 seems to play a key role in transcription of the RNA genome of SARS-CoV-2. Virtual screening by docking and molecular dynamics suggests that lapachol derivatives can interact with Nsp9 from SARS-CoV-2. Complexes of lapachol derivatives V, VI, VIII, IX, and XI with the Nsp9 RNA binding site were subjected to molecular dynamics assays, to assess the stability of the complexes via RMSD. All complexes were stable over the course of 100 ns dynamics assays. Analyses of the hydrogen bonds in the complexes showed that lapachol derivatives VI and IX demonstrated strongest binding, with a stable or increasing number of hydrogen bonds over time. Our results demonstrate that Nsp9 from SARS-CoV-2 could be an important target in prospecting for ligands with antiviral potential. In addition, we showed that lapachol derivatives are potential ligands for SARS-CoV-2 Nsp9. Communicated by Ramaswamy H. Sarma
doi_str_mv 10.1080/07391102.2021.1875050
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7832454</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2480454901</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-cbca66cf287e0a83bf647d9fe085db8f85375a1d0a85bfa9d1390823f669d93a3</originalsourceid><addsrcrecordid>eNp9kU1vEzEQhi0EoqHwE0A-ctngj_Wu94KoogKVqiK1has164_GyLGDvQnqv8erpBW99DTSzDPvfLwIvadkSYkkn0jPB0oJWzLC6JLKXhBBXqAFFVw2hIn2JVrMTDNDJ-hNKb9JJWlPX6MTztte8pYt0NVFxMUHrxO2ewg7mHyKODkcYAt6nQI2Nvt9Te9twaOPxsc7PCU8rS2-KtthZm_Orm-aVfrVsLfolYNQ7LtjPEU_v57frr43lz--XazOLhvddnJq9Kih67RjsrcEJB9d1_ZmcJZIYUbppOC9AGpqTYwOBkP5QCTjrusGM3Dgp-jzQXe7GzfWaBunDEFts99AvlcJvHpaiX6t7tJe1bNZK9oq8PEokNOfnS2T2viibQgQbdoVxVpJKjcQWlFxQHVOpWTrHsdQomYv1IMXavZCHb2ofR_-3_Gx6-H5FfhyAHx0KW_gb8rBqAnuQ8ouQ9S-KP78jH-9tZiA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2480454901</pqid></control><display><type>article</type><title>In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2</title><source>Taylor and Francis Science and Technology Collection</source><creator>Junior, Nilson Nicolau ; Santos, Igor Andrade ; Meireles, Bruno Amaral ; Nicolau, Mariana Sant'Anna Pereira ; Lapa, Igor Rodrigues ; Aguiar, Renato Santana ; Jardim, Ana Carolina Gomes ; José, Diego Pandeló</creator><creatorcontrib>Junior, Nilson Nicolau ; Santos, Igor Andrade ; Meireles, Bruno Amaral ; Nicolau, Mariana Sant'Anna Pereira ; Lapa, Igor Rodrigues ; Aguiar, Renato Santana ; Jardim, Ana Carolina Gomes ; José, Diego Pandeló</creatorcontrib><description>SARS-CoV-2 is the etiological agent of COVID-19, which represents a global health emergency that was rapidly declared a pandemic by the World Health Organization. Currently, there is a dearth of effective targeted therapies against viruses. Natural products isolated from traditional herbal plants have had a huge impact on drug development aimed at various diseases. Lapachol is a 1,4- naphthoquinone compound that has been demonstrated to have therapeutic effects against several diseases. SARS-CoV-2 non-structural proteins (nsps) play an important role in the viral replication cycle. Nsp9 seems to play a key role in transcription of the RNA genome of SARS-CoV-2. Virtual screening by docking and molecular dynamics suggests that lapachol derivatives can interact with Nsp9 from SARS-CoV-2. Complexes of lapachol derivatives V, VI, VIII, IX, and XI with the Nsp9 RNA binding site were subjected to molecular dynamics assays, to assess the stability of the complexes via RMSD. All complexes were stable over the course of 100 ns dynamics assays. Analyses of the hydrogen bonds in the complexes showed that lapachol derivatives VI and IX demonstrated strongest binding, with a stable or increasing number of hydrogen bonds over time. Our results demonstrate that Nsp9 from SARS-CoV-2 could be an important target in prospecting for ligands with antiviral potential. In addition, we showed that lapachol derivatives are potential ligands for SARS-CoV-2 Nsp9. Communicated by Ramaswamy H. Sarma</description><identifier>ISSN: 0739-1102</identifier><identifier>EISSN: 1538-0254</identifier><identifier>DOI: 10.1080/07391102.2021.1875050</identifier><identifier>PMID: 33478342</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>COVID-19 ; lapachol derivatives ; Nsp9 ; SARS-CoV-2</subject><ispartof>Journal of biomolecular structure &amp; dynamics, 2022-07, Vol.40 (13), p.5917-5931</ispartof><rights>2021 Informa UK Limited, trading as Taylor &amp; Francis Group 2021</rights><rights>2021 Informa UK Limited, trading as Taylor &amp; Francis Group 2021 Informa UK Limited, trading as Taylor &amp; Francis Group</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-cbca66cf287e0a83bf647d9fe085db8f85375a1d0a85bfa9d1390823f669d93a3</citedby><cites>FETCH-LOGICAL-c468t-cbca66cf287e0a83bf647d9fe085db8f85375a1d0a85bfa9d1390823f669d93a3</cites><orcidid>0000-0002-3243-5688</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33478342$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Junior, Nilson Nicolau</creatorcontrib><creatorcontrib>Santos, Igor Andrade</creatorcontrib><creatorcontrib>Meireles, Bruno Amaral</creatorcontrib><creatorcontrib>Nicolau, Mariana Sant'Anna Pereira</creatorcontrib><creatorcontrib>Lapa, Igor Rodrigues</creatorcontrib><creatorcontrib>Aguiar, Renato Santana</creatorcontrib><creatorcontrib>Jardim, Ana Carolina Gomes</creatorcontrib><creatorcontrib>José, Diego Pandeló</creatorcontrib><title>In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2</title><title>Journal of biomolecular structure &amp; dynamics</title><addtitle>J Biomol Struct Dyn</addtitle><description>SARS-CoV-2 is the etiological agent of COVID-19, which represents a global health emergency that was rapidly declared a pandemic by the World Health Organization. Currently, there is a dearth of effective targeted therapies against viruses. Natural products isolated from traditional herbal plants have had a huge impact on drug development aimed at various diseases. Lapachol is a 1,4- naphthoquinone compound that has been demonstrated to have therapeutic effects against several diseases. SARS-CoV-2 non-structural proteins (nsps) play an important role in the viral replication cycle. Nsp9 seems to play a key role in transcription of the RNA genome of SARS-CoV-2. Virtual screening by docking and molecular dynamics suggests that lapachol derivatives can interact with Nsp9 from SARS-CoV-2. Complexes of lapachol derivatives V, VI, VIII, IX, and XI with the Nsp9 RNA binding site were subjected to molecular dynamics assays, to assess the stability of the complexes via RMSD. All complexes were stable over the course of 100 ns dynamics assays. Analyses of the hydrogen bonds in the complexes showed that lapachol derivatives VI and IX demonstrated strongest binding, with a stable or increasing number of hydrogen bonds over time. Our results demonstrate that Nsp9 from SARS-CoV-2 could be an important target in prospecting for ligands with antiviral potential. In addition, we showed that lapachol derivatives are potential ligands for SARS-CoV-2 Nsp9. Communicated by Ramaswamy H. Sarma</description><subject>COVID-19</subject><subject>lapachol derivatives</subject><subject>Nsp9</subject><subject>SARS-CoV-2</subject><issn>0739-1102</issn><issn>1538-0254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kU1vEzEQhi0EoqHwE0A-ctngj_Wu94KoogKVqiK1has164_GyLGDvQnqv8erpBW99DTSzDPvfLwIvadkSYkkn0jPB0oJWzLC6JLKXhBBXqAFFVw2hIn2JVrMTDNDJ-hNKb9JJWlPX6MTztte8pYt0NVFxMUHrxO2ewg7mHyKODkcYAt6nQI2Nvt9Te9twaOPxsc7PCU8rS2-KtthZm_Orm-aVfrVsLfolYNQ7LtjPEU_v57frr43lz--XazOLhvddnJq9Kih67RjsrcEJB9d1_ZmcJZIYUbppOC9AGpqTYwOBkP5QCTjrusGM3Dgp-jzQXe7GzfWaBunDEFts99AvlcJvHpaiX6t7tJe1bNZK9oq8PEokNOfnS2T2viibQgQbdoVxVpJKjcQWlFxQHVOpWTrHsdQomYv1IMXavZCHb2ofR_-3_Gx6-H5FfhyAHx0KW_gb8rBqAnuQ8ouQ9S-KP78jH-9tZiA</recordid><startdate>20220721</startdate><enddate>20220721</enddate><creator>Junior, Nilson Nicolau</creator><creator>Santos, Igor Andrade</creator><creator>Meireles, Bruno Amaral</creator><creator>Nicolau, Mariana Sant'Anna Pereira</creator><creator>Lapa, Igor Rodrigues</creator><creator>Aguiar, Renato Santana</creator><creator>Jardim, Ana Carolina Gomes</creator><creator>José, Diego Pandeló</creator><general>Taylor &amp; Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3243-5688</orcidid></search><sort><creationdate>20220721</creationdate><title>In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2</title><author>Junior, Nilson Nicolau ; Santos, Igor Andrade ; Meireles, Bruno Amaral ; Nicolau, Mariana Sant'Anna Pereira ; Lapa, Igor Rodrigues ; Aguiar, Renato Santana ; Jardim, Ana Carolina Gomes ; José, Diego Pandeló</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-cbca66cf287e0a83bf647d9fe085db8f85375a1d0a85bfa9d1390823f669d93a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>COVID-19</topic><topic>lapachol derivatives</topic><topic>Nsp9</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Junior, Nilson Nicolau</creatorcontrib><creatorcontrib>Santos, Igor Andrade</creatorcontrib><creatorcontrib>Meireles, Bruno Amaral</creatorcontrib><creatorcontrib>Nicolau, Mariana Sant'Anna Pereira</creatorcontrib><creatorcontrib>Lapa, Igor Rodrigues</creatorcontrib><creatorcontrib>Aguiar, Renato Santana</creatorcontrib><creatorcontrib>Jardim, Ana Carolina Gomes</creatorcontrib><creatorcontrib>José, Diego Pandeló</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of biomolecular structure &amp; dynamics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Junior, Nilson Nicolau</au><au>Santos, Igor Andrade</au><au>Meireles, Bruno Amaral</au><au>Nicolau, Mariana Sant'Anna Pereira</au><au>Lapa, Igor Rodrigues</au><au>Aguiar, Renato Santana</au><au>Jardim, Ana Carolina Gomes</au><au>José, Diego Pandeló</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2</atitle><jtitle>Journal of biomolecular structure &amp; dynamics</jtitle><addtitle>J Biomol Struct Dyn</addtitle><date>2022-07-21</date><risdate>2022</risdate><volume>40</volume><issue>13</issue><spage>5917</spage><epage>5931</epage><pages>5917-5931</pages><issn>0739-1102</issn><eissn>1538-0254</eissn><abstract>SARS-CoV-2 is the etiological agent of COVID-19, which represents a global health emergency that was rapidly declared a pandemic by the World Health Organization. Currently, there is a dearth of effective targeted therapies against viruses. Natural products isolated from traditional herbal plants have had a huge impact on drug development aimed at various diseases. Lapachol is a 1,4- naphthoquinone compound that has been demonstrated to have therapeutic effects against several diseases. SARS-CoV-2 non-structural proteins (nsps) play an important role in the viral replication cycle. Nsp9 seems to play a key role in transcription of the RNA genome of SARS-CoV-2. Virtual screening by docking and molecular dynamics suggests that lapachol derivatives can interact with Nsp9 from SARS-CoV-2. Complexes of lapachol derivatives V, VI, VIII, IX, and XI with the Nsp9 RNA binding site were subjected to molecular dynamics assays, to assess the stability of the complexes via RMSD. All complexes were stable over the course of 100 ns dynamics assays. Analyses of the hydrogen bonds in the complexes showed that lapachol derivatives VI and IX demonstrated strongest binding, with a stable or increasing number of hydrogen bonds over time. Our results demonstrate that Nsp9 from SARS-CoV-2 could be an important target in prospecting for ligands with antiviral potential. In addition, we showed that lapachol derivatives are potential ligands for SARS-CoV-2 Nsp9. Communicated by Ramaswamy H. Sarma</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>33478342</pmid><doi>10.1080/07391102.2021.1875050</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-3243-5688</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0739-1102
ispartof Journal of biomolecular structure & dynamics, 2022-07, Vol.40 (13), p.5917-5931
issn 0739-1102
1538-0254
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7832454
source Taylor and Francis Science and Technology Collection
subjects COVID-19
lapachol derivatives
Nsp9
SARS-CoV-2
title In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T23%3A00%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20silico%20evaluation%20of%20lapachol%20derivatives%20binding%20to%20the%20Nsp9%20of%20SARS-CoV-2&rft.jtitle=Journal%20of%20biomolecular%20structure%20&%20dynamics&rft.au=Junior,%20Nilson%20Nicolau&rft.date=2022-07-21&rft.volume=40&rft.issue=13&rft.spage=5917&rft.epage=5931&rft.pages=5917-5931&rft.issn=0739-1102&rft.eissn=1538-0254&rft_id=info:doi/10.1080/07391102.2021.1875050&rft_dat=%3Cproquest_pubme%3E2480454901%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c468t-cbca66cf287e0a83bf647d9fe085db8f85375a1d0a85bfa9d1390823f669d93a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2480454901&rft_id=info:pmid/33478342&rfr_iscdi=true